These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26000884)

  • 1. Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling.
    Bhardwaj A; Ganesan N; Tachibana K; Rajapakshe K; Albarracin CT; Gunaratne PH; Coarfa C; Bedrosian I
    PLoS One; 2015; 10(5):e0127678. PubMed ID: 26000884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
    Yanai A; Inoue N; Yagi T; Nishimukai A; Miyagawa Y; Murase K; Imamura M; Enomoto Y; Takatsuka Y; Watanabe T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):197-203. PubMed ID: 25600244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
    Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
    Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells.
    de Graauw M; van Miltenburg MH; Schmidt MK; Pont C; Lalai R; Kartopawiro J; Pardali E; Le Dévédec SE; Smit VT; van der Wal A; Van't Veer LJ; Cleton-Jansen AM; ten Dijke P; van de Water B
    Proc Natl Acad Sci U S A; 2010 Apr; 107(14):6340-5. PubMed ID: 20308542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
    Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
    Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers.
    Raulf N; Lucarelli P; Thavaraj S; Brown S; Vicencio JM; Sauter T; Tavassoli M
    Eur J Cancer; 2018 Oct; 102():52-68. PubMed ID: 30142511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer.
    Wang J; Ji H; Niu X; Yin L; Wang Y; Gu Y; Li D; Zhang H; Lu M; Zhang F; Zhang Q
    Dis Markers; 2020; 2020():6103542. PubMed ID: 32377271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
    Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
    Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANXA4 Activates JAK-STAT3 Signaling by Interacting with ANXA1 in Basal-Like Breast Cancer.
    Li L; Zhang R; Liu Y; Zhang G
    DNA Cell Biol; 2020 Sep; 39(9):1649-1656. PubMed ID: 32552056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Annexin A1 Expression Is Associated with Epithelial-Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer.
    Oshi M; Tokumaru Y; Mukhopadhyay S; Yan L; Matsuyama R; Endo I; Takabe K
    Cells; 2021 Mar; 10(3):. PubMed ID: 33804148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cell-Based Systematic Review on the Role of Annexin A1 in Triple-Negative Breast Cancers.
    Pearanpan L; Nordin FJ; Siew EL; Kumolosasi E; Mohamad Hanif EA; Masre SF; Chua EW; Cheng HS; Rajab NF
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling.
    Luoh SW; Wagoner W; Wang X; Hu Z; Lai X; Chin K; Sears R; Ramsey E
    Mol Carcinog; 2019 May; 58(5):699-707. PubMed ID: 30604896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.
    Chen L; Yuan Y; Kar S; Kanchi MM; Arora S; Kim JE; Koh PF; Yousef E; Samy RP; Shanmugam MK; Tan TZ; Shin SW; Arfuso F; Shen HM; Yang H; Goh BC; Park JI; Gaboury L; Lobie PE; Sethi G; Lim LHK; Kumar AP
    Mol Cancer Ther; 2017 Nov; 16(11):2528-2542. PubMed ID: 29021293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
    Jhaveri K; Teplinsky E; Silvera D; Valeta-Magara A; Arju R; Giashuddin S; Sarfraz Y; Alexander M; Darvishian F; Levine PH; Hashmi S; Zolfaghari L; Hoffman HJ; Singh B; Goldberg JD; Hochman T; Formenti S; Esteva FJ; Moran MS; Schneider RJ
    Clin Breast Cancer; 2016 Apr; 16(2):113-22.e1. PubMed ID: 26774497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
    Sengupta S; Schiff R; Katzenellenbogen BS
    Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
    Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
    Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis.
    Okano M; Oshi M; Butash AL; Katsuta E; Tachibana K; Saito K; Okayama H; Peng X; Yan L; Kono K; Ohtake T; Takabe K
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31461932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.